Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100118 | 0.90 | ABL1 (0.70) | ABL1SLC6A4SLC6A3NR4A2KMT2A | |
| SCHEMBL1957006 | 0.85 | ABL1 (0.64) | ABL1SLC6A4SLC6A3NR4A2KMT2A | |
| SCHEMBL1955327 | 0.85 | ABL1 (0.64) | ABL1SLC6A4SLC6A3NR4A2KMT2A | |
| SCHEMBL16960600 | 0.85 | ABL1 (0.64) | ABL1SLC6A4SLC6A3NR4A2KMT2A | |
| SCHEMBL20117002 | 0.84 | ALDH1A1 (0.50) | ABL1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23035401 | 0.81 | ABL1 (0.64) | ABL1SLC6A4SLC6A3NR4A2KMT2A | |
| SCHEMBL5129370 | 0.81 | ABL1 (0.64) | ABL1SLC6A4SLC6A3NR4A2KMT2A | |
| SCHEMBL608814 | 0.81 | ABL1 (0.68) | ABL1NR4A2KMT2AMEN1ALDH1A1 | |
| SCHEMBL4363906 | 0.81 | ABL1 (0.62) | ABL1SLC6A4SLC6A3NR4A2KMT2A | |
| SCHEMBL10028293 | 0.80 | ABL1 (0.57) | ABL1SLC6A4SLC6A3NR4A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-05-25 | — | — | US | disclosed |
| WO-2021203014-A1 | PYRANO[4,3-B]L NDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3037416-A1 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | Bristol-Myers Squibb Holdings Ireland (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-3037416-A1 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | Bristol-Myers Squibb Holdings Ireland (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2326624-B1 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-30 | — | — | US | disclosed |
| US-8207341-B2 | Process or synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207341-B2 | Process or synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207341-B2 | Process or synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2326624-A2 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010027889-A2 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027889-A2 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-04 | — | — | US | disclosed |
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-04 | — | — | US | disclosed |
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | ABL1 8/4885SLC6A4 404/4885SLC6A3 917/4885 |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | ABL1 8/4885SLC6A4 404/4885SLC6A3 917/4885 |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | ABL1 4764/4885SLC6A4 3533/4885SLC6A3 4010/4885 |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | ABL1 8/4885SLC6A4 404/4885SLC6A3 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.